Teltonika‘s smart medical watch shows promising results in first testing of detection of atrial fibrillationTELTONIKA TELEMEDIC has combined forces with Kaunas University of Technology (KTU) and Vilnius University (VU) in developing a smart medical watch to determine atrial fibrillation. Now we are happy to share the results of our first testing with patients.
Atrial fibrillation (AF) is considered as one of the most growing and serious global health problems in our ageing society worldwide. The condition is an absolute arrhythmia characterized by irregular heartbeats and absence of P waves in ECG. Possible devastating consequences include forming of blood clots which may lead to stroke and other embolic events, as well as de novo induction or worsening of heart failure with serious reduction of quality of life and survival. 33,5 million people are suffering from this disease worldwide, while on average, 1 million strokes are linked to it every year.
Emerging e-health technologies for atrial fibrillation detection are now essential in empowering physicians to perform early diagnosis of AF both in-hospital and out-of-hospital which may lead to earlier mortality-reducing therapy (e. g. anticoagulants). Since the start of cooperation in summer, the most talented engineers from Teltonika Telemedic have been working on medical IoT device based on the KTU and VU algorithms.
The aim of this project is to create a smartwatch that provides long-term heart rhythm monitoring and a multiple-lead electrocardiography (ECG). This means that the smartwatch will not only be able to continuously monitor the heart’s activity and alert about possible atrial fibrillation detection in a timely manner but also to confirm or exclude it with the use of medically approved ECG.
For the past months, we were committed to testing all the algorithms for the future smartwatch and now we are excited to shed some light on the ongoing research and promising results.
The wrist-worn device works as an integrated diagnostic system of two components: a photoplethysmography-based (PPG) AF detection algorithm and a wireless modified ECG of multiple leads. Since our cooperation with the universities began, we were conducting various tests to measure the ability of our wristband device to differentiate between Atrial Fibrillation (AF) and sinus rhythm (SR). Also, one of the aims was to determine the accuracy of the device. For the test, we’ve recruited >460 people with AF and control groups of SR with/without frequent premature atrial/ventricular complexes (PACs/PVCs).
To measure the accuracy of our smartwatch, a validated external ECG device was used to record a nearly simultaneous 3-lead continuous ECG to monitor the heart rhythm. Once the PPG algorithm detected AF, a vibration alarm on the wristband device was triggered. Two independent diagnosis-blinded cardiologists assessed the ECG tracings as “AF”, “SR” or “Cannot be concluded”.
Atrial fibrillation detection preliminary results using photoplethysmography, wrist-worn device written ECG and both methods combined.
Conducted tests have shown 95.7% accuracy while using photoplethysmography algorithm and 98.1% accuracy with regard to ECG screening. These preliminary results indicated that in the test stage our device already meets high standards of precision.
According to our medical experts working on this project, the above-mentioned results can be considered as very promising. However, we believe that our talented team can improve these numbers even more.
Our team will continue working on the technical aspects and design of the smartwatch, and we will keep you updated. Meanwhile, if you have any questions or you would like to be the first company to order the pilot order, please do not hesitate to contact us: email@example.com